Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MercadoLibre

Okta

PayPal

A combination of solid earnings and investor optimism has many of the year's losers seeing some gains.

Tech Stocks Surging: 5 Stocks Sending the Nasdaq Higher on Wednesday

Devon Energy

Pfizer

Tesla

When a company's return on equity ratio is superior to most of its competitors, it generally indicates the company has been very efficient in generating profits. Thus, investors may want to consider the following stocks, since they are performing better than most of their peer group companies in terms of a higher ROE ratio.

4 Stocks With High Return on Equity

Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program.

Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program

Moderna, Inc. (NASDAQ:MRNA ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stephane Bancel - Chief Executive Officer David Meline - Chief Financial Officer Stephen Hoge - President Paul Burton - Chief Medical Officer Arpa Garay - Chief Commercial Officer Conference Call Participants Matthew Harrison - Morgan Stanley Elizabeth Webster - Goldman Sachs Michael Yee - Jefferies Sheldon Fan - Barclays Geoff Meacham - Bank of America Ellie Merle - UBS Operator Good morning. My name is Kevin, and I will be your operator.

Moderna, Inc.'s (MRNA) CEO Stephane Bancel on Q2 2022 Results - Earnings Call Transcript

Investors are cheering the company's Q2 results. But there was a troubling detail in Moderna's update.

Moderna Just Gave Investors 499 Million Reasons to Worry

MRNA) research Coronavirus (Covid 19) vaccine. Row of vaccine bottles with blurred Moderna company logo on background.

Moderna (MRNA) Stock Pops on Strong Sales, Earnings Beat

Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates

Moderna stock jumped Wednesday after sales of the company's Covid vaccine and earnings easily outperformed expectations. The post Moderna Stock Surges After Covid Vaccine Sales Obliterate Expectations appeared first on Investor's Business Daily.

Moderna Stock Surges After Covid Vaccine Sales Obliterate Expectations

Moderna took a nearly $500 million hit on write-downs for vaccine inventory that has expired or is expected to expire before is can be used.

Moderna's 2Q earnings beat expectations, but it writes off $500 million in expiring Covid shots

Shares of Moderna Inc. MRNA, -0.43% gained 3.8% in premarket trading on Wednesday after the company beat earnings and revenue expectations in the second quarter of the year. Moderna had net income of $2.2 billion, or $5.24 per share, in the second quarter of the year, down from $2.8 billion, or $6.46 per share, in the same quarter a year ago.

Moderna's stock rises 3% after beating earnings expectations in the second quarter

Moderna Inc on Wednesday maintained its full-year sales outlook for its COVID-19 vaccine, following a similar prediction by bigger rival Pfizer Inc a week ago, amid tepid demand from low-to-middle income countries.

Moderna retains COVID vaccine sales view on weak demand from low-income nations

Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24 Company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion Company announces new $3 billion share repurchase plan Company has four infectious disease vaccines in Phase 3 and expects data from proof-of-concept studies in rare diseases and immuno-oncology later this year CAMBRIDGE, MA / ACCESSWIRE / August 3, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the second quarter of fiscal year 2022. "Today's earnings represent a strong second quarter performance, with $10.8 billion in revenue for the first half of the year.

Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates

CVS Health

Health care's potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy.

3 Health Care Stocks in Great Financial Health

BioNTech SE

Novavax

The booster market might be a long-term source of revenue.

Could the Fall Booster Market Boost Vaccine Stocks?

Moderna is still prevailing in the omicron booster market in at least one important way.

Why Pfizer and BioNTech Are Beating Moderna in the Omicron Booster Market

Products Are in, Platforms Are Out for Biotech Investors

Moderna's blockbuster product is set for a new wave of demand.

Could This News Change Everything for Moderna?

The biotech keeps up a steady supply of coronavirus vaccine boosters to a very reliable customer.

Why Moderna Was a Stock Market Star on Friday

Moderna and BioNTech are the two mRNA giants behind the dominant COVID vaccines SpikeVax and Comirnaty. The two companies have a great deal in common, and the share prices typically track very close to one another.

Moderna And BioNTech: I Back The Former To Drive Share Price Upside In 2022

Moderna MRNA, +2.57% and Pfizer PFE, -0.33% have not yet started clinical trials for the new COVID-19 shots that are expected to better target the BA.4 and BA.5 strains of the virus.

Moderna and Pfizer to start clinical trials for COVID-19 boosters that target BA.5 ‘in the near future'

Los Angeles County has dropped a plan for a universal indoor face-mask mandate as COVID cases and hospitalizations have stabilized, with community transmission expected to fall to “medium” from “high” in the coming weeks.

LA County dodges face mask mandate as community transmission rates stabilize, and government orders 66 million doses of Moderna's pending booster

Shares of Moderna Inc. MRNA, +0.03% gained 3.8% in premarket trading on Friday after the company said the U.S. will buy 66 million doses of a bivalent COVID-19 booster candidate that can better protect against the BA.5 strain. That vaccine is not yet in clinical trials but studies are expected to begin "in the near future," a Moderna spokesperson told MarketWatch earlier this week.

U.S. to pay Moderna $1.7 billion for 66 million doses of a new COVID-19 vaccine booster

New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses CAMBRIDGE, MA / ACCESSWIRE / July 29, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has secured 66 million doses of a Moderna COVID-19 vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax™ plus the Omicron BA.4/5 strain mRNA. The contract includes an award of up to $1.74 billion for the manufacture and delivery of 66 million doses of mRNA-1273.222, as well as options to purchase up to an additional 234 million doses of COVID-19 vaccine booster candidates from Moderna.

Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses

Moderna is one of the least expensive companies in the S&P 500 in terms of valuation. In this article, we'll examine other aspects of the company.

Is Moderna's Cheaper Valuation A Buying Signal?

This company has 46 treatment programs in development.

News for Moderna Stock (MRNA)